Syquant Capital Sas Blueprint Medicines Corp Transaction History
Syquant Capital Sas
- $302 Million
- Q2 2025
A detailed history of Syquant Capital Sas transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Syquant Capital Sas holds 805,603 shares of BPMC stock, worth $104 Million. This represents 34.24% of its overall portfolio holdings.
Number of Shares
805,603
Previous 805,603
-0.0%
Holding current value
$104 Million
Previous $87.6 Million
17.87%
% of portfolio
34.24%
Previous 34.24%
Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
379Shares Held
68.1MCall Options Held
1.54MPut Options Held
1.21M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$860 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$701 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$498 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$398 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...